Introduction {#s1}
============

The lymphatic vasculature is a blind-ended network of vessels that is essential for tissue fluid balance, absorbance of dietary lipids and surveillance of the immune system in vertebrate homeostasis and has been implicated in cardiovascular disease ([@bib74]), neurodegenerative disorders ([@bib14]), autoimmunity ([@bib43]) and cancer metastasis ([@bib37]). While the formation of systemic lymphatic vasculature, emerging from venous endothelium at around embryonic day (E)10 in mouse, has received considerable attention, how organ-specific lymphatics arise has only recently emerged as a focus of study, including the characterization of lymphatic development in the mouse mesentery ([@bib69]), intestine ([@bib44]), dermis ([@bib55]; [@bib45]), meninges ([@bib1]) and heart ([@bib35]; [@bib70]; [@bib46]; [@bib19]). In contrast, how lymphatic vessels develop within the mouse or human kidney is not well established, despite their functional importance in pathological processes within the mature organ, including renal fibrosis and transplant rejection ([@bib63]; [@bib33]; [@bib53]).

The development of the metanephros, the direct precursor of the mature kidney, commences at around E10.5 in mouse and five post-conceptional weeks (PCW) in humans. Kidney development is a complex process, orchestrated by interactions between epithelial, stromal, immune and blood vascular endothelial cells ([@bib47]). How lymphatic vessels fit within this process is unclear. Our current understanding of kidney lymphatic development is limited to two descriptive studies; a paucity of insight which reflects their apparent scarcity ([@bib54]) and generally deep location within the kidney. Both prior studies draw conclusions based on staining tissue sections of rodent embryonic kidney with single lymphatic markers ([@bib38]; [@bib71]). However, the recent description of hybrid renal vessels with both blood vascular and lymphatic properties ([@bib26]; [@bib32]) and non-endothelial renal cell types expressing lymphatic markers ([@bib23]; [@bib34]) necessitate the simultaneous use of multiple markers to reliably identify lymphatic endothelium in the kidney.

Here, we have characterized the spatiotemporal development of the kidney lymphatic vasculature using a combination of wholemount immunofluorescence, optical clearing and high-resolution confocal microscopy to obtain three-dimensional (3D) images of intact mouse and human fetal kidneys at single-cell resolution. Using this approach, we provide novel insights into lymphatic vessel formation in mammalian kidney development, including a first description of the forming lymphatics in human fetal kidneys. Further, we identified lymphatic anomalies in a mouse model of polycystic kidney disease (PKD), the most common genetic cause of kidney failure.

Results and discussion {#s2}
======================

Spatiotemporal and quantitative dynamics of developing kidney lymphatic vessels in mouse {#s2-1}
----------------------------------------------------------------------------------------

To observe lymphatic vessels during kidney development, we isolated metanephroi from CD-1 outbred wildtype mouse embryos at a range of developmental stages, and wholemount immunolabelled them for the early lymphatic endothelial cell markers ([@bib2]; [@bib78]) prospero homeobox protein 1 (PROX1) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1). We then optically cleared and imaged entire labelled kidneys using confocal microscopy. 3D reconstructions and *z-*stacks of confocal images revealed a cellular network of PROX1^+^/LYVE-1^+^ lymphatic endothelial cells in the E14.5 mouse kidney ([Figure 1A](#fig1){ref-type="fig"}). At this stage in development, the ureteric bud, has already undergone 8--9 generations of branching ([@bib67]) and the kidney contains a rich, perfused blood vasculature ([@bib42]; [@bib49]; [@bib62]). No definitive PROX1^+^/LYVE-1^+^ vessels were observed in the kidney prior to E14.5 (data not shown). By E16.5, the kidney lymphatics constituted a vascular plexus, that contained some lumenized vessel segments ([Figure 1---video 1](#fig1video1){ref-type="video"}). By E18.5, lymphatic vessel branches were observed distally in the kidney. We confirmed the lymphatic identity of the plexus ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) by its prominent expression of vascular endothelial growth factor receptor 3 (VEGFR-3) and podoplanin ([@bib6]; [@bib29]) at E15.5 and weak expression of the blood endothelial marker endomucin relative to surrounding blood vasculature ([@bib69]; [@bib21]).

![Visual and quantitative characterization of lymphatic vessels during mouse kidney development.\
(**A**) Appearance of PROX1^+^/LYVE-1^+^ lymphatic endothelium (white arrowheads) in E14.5, E16.5 and E18.5 mouse kidneys. Representative 3D reconstructions and confocal *z*-stacks from a minimum of four kidneys per timepoint from three independent embryonic litters. Dashed boxes in the 3D reconstructions represent the location of the lymphatic plexus and indicate area shown at higher magnification in the bottom of each panel. Strong LYVE-1 staining was also observed in macrophages from E14.5 through to E18.5 (yellow asterisks). Weak PROX1 staining was observed in tubular epithelium from E16.5 onwards (blue asterisks). 3D reconstruction scalebars: 100 μm (E14.5, E16.5); 200 μm (E18.5). Confocal z-stack scalebars: 50 μm. (**B**) Volume renderings of the lymphatic plexus and embryonic kidneys at E14.5, E16.5 and E18.5; top panels show the lymphatic plexus and kidney from a coronal view; bottom panels show the sagittal view looking down upon the plexus towards the hilum. Scalebars: 50 μm (E14.5); 100 μm (E16.5); 500 μm (E18.5). The sagittal views are not to scale. (**C**) Quantitative analysis of kidney lymphatic vessel development at E14.5 (*n* = 5), E15.5 (*n* = 5), E16.5 (*n* = 4), E17.5 (*n* = 5) and E18.5 (*n* = 6). Each data point represents a whole kidney immunolabelled for PROX1 and LYVE-1 and error bars represent standard error of the mean. ANOVA showed significant increases in the number of lymphatic vessel branches per kidney (*F* = 8.5; p=0.0003), the range of vessel lengths (*F =* 20.6; p*\<*0.0001), the maximum vessel diameter (*F =* 5.7; p*=*0.003) and total network volume (*W =* 10.6; p*=*0.0022). For the total volume of the lymphatic network, we used Welch's ANOVA, as equality of variance was not met for this parameter. Brackets between timepoints demonstrate significance when multiple comparisons were performed using Bonferroni tests (or Tamhane T2 multiple comparison testing for total network volume). \*: p*\<*0.0332; \*\*: p\<0.0021; \*\*\*: p\<0.0002, \*\*\*\*: p\<0.0001. Raw data and results of all multiple comparisons are presented in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
Figure 1---source data 1.This spreadsheet contains the numerical raw data and statistics for the quantitative analysis of kidney lymphatic vessel development shown in [Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}.](elife-48183-fig1){#fig1}

Using a computational approach for the segmentation and volume rendering of PROX1^+^/LYVE-1^+^ vessels, we created 3D models of lymphatic development in the mouse embryonic kidney ([Figure 1B](#fig1){ref-type="fig"}, and [Figure 1---video 2](#fig1video2){ref-type="video"}). These models visually depict the progressive remodeling of kidney lymphatic vessels from E14.5 through to E18.5. At all stages we observed a ring-like anastomosis in the renal hilum, from which lymphatic vessels originated. These vessels branched and increased in length over the course of renal development. The 3D models conveyed that large volumes of the embryonic kidney were unoccupied by lymphatic vessels, demonstrating that kidney lymphatics are sparse compared to blood vasculature at equivalent stages ([@bib49]; [@bib15]; [@bib66]). We then used uroplakin (UPK3A), platelet endothelial cell adhesion molecule-1 (PECAM-1), aquaporin 2 (AQP2) and alpha smooth muscle actin (αSMA) to clarify the spatial relationship of lymphatic vessels to other structures within the developing kidney ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). We found that the ring-like lymphatic anastomosis resided under the nascent renal pelvis; identified by the urothelial marker UPK3A ([Figure 1---video 3](#fig1video3){ref-type="video"}). PECAM-1^+^ blood endothelium and lymphatic vasculature run alongside each other in the kidney, as shown in other organs ([@bib44]; [@bib35]). Whereas αSMA was expressed around the PECAM-1^+^ renal arterial system at E18.5, as previously described ([@bib56]), we did not detect αSMA around PROX1^+^ vessels. This suggests that pre-collectors or collector vessels have not yet formed by this time-point or that lymphatics within the kidney are capillaries that lack mural cell coverage ([@bib76]). We labelled collecting duct epithelium with AQP2 to delineate the renal medulla and found no lymphatic vessels in this region of the kidney ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). At no point were lymphatics observed near or within the renal capsule.

Quantitative analysis of 3D imaging has provided novel insights into mouse kidney development, such as the stereotypical nature of ureteric bud branching and the cellular dynamics of the progenitor niches that eventually form the nephron, the functional unit of the kidney ([@bib67]; [@bib68]; [@bib51]). To perform the first quantitative 3D analysis of kidney lymphatic vessel development, we segmented and analyzed PROX1^+^/LYVE-1^+^ vessels from entire mouse embryonic kidneys using filament tracing software to measure the number of kidney lymphatic vessel branches including lengths, mean diameters and volumes for each vessel branch. From these data, we quantified vascular parameters: the range of vessel branch lengths, the maximum vessel branch diameter and the total volume of all branches constituting the lymphatic network between E14.5 and E18.5 ([Figure 1C](#fig1){ref-type="fig"}). Overall, between E14.4 and E18.5, the total number of lymphatic vessel branches increased over five-fold (p*=*0.0003); the range of vessel lengths increased approximately three-fold (p\<0.0001); the maximum diameter approximately doubled (p*=*0.003); and the total network volume increased by a factor of 18 (p*=*0.0006). During this time, the volume of the kidney expands over 40-fold ([@bib67]) and mature renal cell types emerge in the kidney including pericytes and mesangial cells ([@bib48]), podocytes and all the components of the differentiated nephron ([@bib12]). We then compared kidneys at intermediate timepoints between E14.5 and E18.5. No lymphatic vascular parameters increased significantly between E14.5 and E15.5. In contrast, between E15.5 and E18.5, we observed a significant increase in the total number of vessel branches (p*=*0.0038), their range of lengths (p*\<*0.0001), maximum diameter (p*=*0.0166) and total network volume (p*=*0.0429). There were further significant increases in the number of vessel branches between E15.5 and E17.5 (p*=*0.0322) and the range of vessel lengths between E16.5 (p*=*0.0039) or E17.5 (p*=*0.0154) when compared to E18.5.

By pooling values for lymphatic vessel branch parameters for all kidneys at each timepoint, we generated histograms conveying the increase in vessel number and branch length, diameter and volume at each timepoint. The change in shape of histograms between each timepoint were less pronounced between E14.5 and E15.5, suggesting rapid remodeling of the plexus after E15.5 ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Together, our quantitative approach suggests a period of quiescence in the early stages of kidney lymphatic vessel development, followed by a progressive increase in lymphatic expansion after E15.5. This timing just precedes the initiation of excretory function by the kidney ([@bib47]; [@bib9]) and also coincides with the appearance of primitive erythrocytes in renal vasculature ([@bib49]) and a wave of development of vascularized glomerular capillary loops ([@bib25]).

The rapid expansion of the lymphatic plexus from E15.5 onwards could be driven by the accumulation of interstitial fluid, which has extravasated from the renal vasculature and stimulates lymphatic expansion ([@bib57]). Additionally, either the recruitment of progenitor cells, as previously suggested for other organs ([@bib17]; [@bib31]), or cellular and paracrine factors may be responsible ([@bib73]). One critical paracrine factor is vascular endothelial growth factor C (VEGF-C), which binds to VEGFR-3 and promotes the sprouting and migration of lymphatic endothelial cells ([@bib55]; [@bib21]; [@bib30]). To explore the expression of VEGF-C in the developing kidney, we used mice carrying *LacZ* under the control of the endogenous *Vegfc* regulatory region ([@bib30]) ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Wholemount X-gal staining of E15.5 kidneys from heterozygous embryos (*Vegfc^LacZ/+^*) demonstrated β-galactosidase (β-gal) activity in a branching pattern, mimicking the appearance of the renal arterial tree. Sections of X-gal-stained E16.5 *Vegfc^LacZ/+^* kidneys showed β-gal activity to be restricted to interstitial cells beneath the pelvis and adjacent arterioles. We further stained these sections for LYVE-1 and observed lumenized LYVE-1^+^ vessels in the hilum surrounded by β-gal-expressing interstitial cells. Together, these findings convey that the renal hilum; where kidney lymphatics first arise, is a VEGF-C-rich niche.

Characterization of conserved lymphatic endothelial cell clusters in the developing mammalian kidney {#s2-2}
----------------------------------------------------------------------------------------------------

During embryonic development and in the early postnatal period, lymphatics form by sprouting from veins and pre-existing lymphatics; a process termed lymphangiogenesis, and the assembly of lymphatic progenitors; a process termed lymphvasculogenesis ([@bib59]). A hallmark of lymphvasculogenesis is the presence of isolated clusters of lymphatic endothelial cells, as observed during the development of mesenteric, meningeal, dermal and cardiac lymphatic vasculature ([@bib69]; [@bib55]; [@bib45]; [@bib1]; [@bib70]; [@bib19]). By inspecting confocal image stacks of E16.5 mouse embryonic kidneys, we found PROX1^+^/LYVE-1^+^ cellular clusters, which were structurally distinct from the lymphatic vessel plexus ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---video 1](#fig2video1){ref-type="video"}). We confirmed the lymphatic identity of these clusters by their expression of VEGFR-3 and podoplanin at E15.5 and E16.5 ([Figure 2B](#fig2){ref-type="fig"}). LYVE-1, VEGFR-3 and podoplanin all highlighted filopodia-like processes extending from lymphatic clusters in the kidney, likely analogous to the migratory tips that extend from nascent lymphatic endothelium ([@bib79]). We performed further immunolabelling to characterize the molecular profile of the clusters ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The PROX1^+^/LYVE-1^+^ clusters did not express the murine macrophage marker F4/80 ([@bib50]). Relative to renal blood vasculature, PECAM-1 and endomucin were weakly expressed by lymphatic clusters, supporting their non-blood vascular endothelial identity ([@bib58]).

![Isolated lymphatic endothelial cell clusters in the mouse embryonic kidney that form in response to VEGF-C.\
(**A**) In the developing kidney, PROX1^+^/LYVE-1^+^ lymphatic endothelial cells appear as either vessels or cell clusters. A representative image from analysis of four kidneys from three independent litters. Lymphatic clusters (white arrowheads) at E16.5 are structurally and anatomically distinguishable from the lymphatic plexus (white asterisk). The segmentation of PROX1^+^/LYVE-1^+^ lymphatics makes clusters easier to visualize. Scalebar: 50 μm. H, hilum; C, cortex. (**B**) Confirmation of the lymphatic identity of clusters. Representative confocal *z*-stacks from a minimum of 3 kidneys from three independent litters stained for PROX1, LYVE-1, podoplanin and VEGFR-3 identifies lymphatic clusters (white arrowhead). Filopodia-like projections (white asterisks) extend from the clusters. The relationship of clusters to other structures in the kidney is also shown. Scalebars: 20 μm. BE, blood endothelium; G, glomerulus; Mφ, macrophage. (**C**) Quantitative assessment of lymphatic cluster dynamics during mouse kidney development. For each embryonic kidney immunolabelled for PROX1 and LYVE-1, the number of clusters (top graph) or the total number of cells within all clusters (bottom graph) in any single kidney was quantified. Each data point represents the values for one kidney and error bars represent standard error of the mean. ANOVA showed a significant overall increase in the total number of clusters per kidney (*F =* 10.9; p*=*0.0002) and the total number of cells constituting all clusters per kidney (*F =* 15.9; p*\<*0.0001). Brackets between timepoints demonstrate significance when multiple comparisons were performed using Bonferroni tests. \*: p*\<*0.0332; \*\*: p\<0.0021; \*\*\*: p\<0.0002, \*\*\*\*: p\<0.0001. Raw data and results of all multiple comparisons are presented in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. (**D**) Volume renderings of a representative E15.5 kidney conveys the heterogeneity of PROX1^+^/LYVE-1^+^ cluster size and morphology. Scalebar: 5 μm. (**E**) VEGF-C increases the abundance of lymphatic clusters ex vivo. Representative 3D reconstructions of mouse embryonic kidneys, harvested at E14.5, cultured at the air-liquid interface for 48 hr with or without 40 ng/ml recombinant VEGF-C and immunolabelled for PROX1 and LYVE-1. PROX1^+^/LYVE-1^+^ lymphatic cell clusters (white arrowheads) were detectable in both treated and untreated explants. The number of PROX1^+^/LYVE-1^+^ lymphatic cell clusters per kidney was quantified. Each data point represents the values for one cultured kidney and error bars represent standard error of the mean. An unpaired Student's *t-*test showed that treatment with VEGF-C significantly increased the abundance of PROX1^+^/LYVE-1^+^ cell clusters within the explants (*t =* 2.77; p=0.0184). Data were pooled from two independent culture experiments. Raw data and results of statistical tests are presented in [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}.\
Figure 2---source data 1.This spreadsheet contains the numerical raw data and statistics for the quantitative analysis of kidney lymphatic endothelial cell cluster dynamics in vivo, shown in [Figure 2C](#fig2){ref-type="fig"}.\
Figure 2---source data 2.This spreadsheet contains the numerical raw data and statistics comparing the effect of VEGF-C treatment on lymphatic endothelial cell cluster number in mouse embryonic kidney explants, shown in [Figure 2E](#fig2){ref-type="fig"}.](elife-48183-fig2){#fig2}

As our imaging technique captured entire mouse embryonic kidneys at single-cell resolution, we were able to use a quantitative approach to assess the dynamics of lymphatic endothelial cell clusters during kidney development. For each embryonic kidney, we counted the frequency of PROX1^+^/LYVE-1^+^ clusters and quantified the total number of cells constituting all clusters within each kidney ([Figure 2C](#fig2){ref-type="fig"}). Between E14.5 and E16.5 there was a significant increase in both the frequency of clusters (p*=*0.0001) and number of total cluster cells (p*\<*0.0001). Both parameters peaked at E16.5 but after E16.5, both frequency (p*\<*0.0064) and number of total cluster cells (p*\<*0.0064) declined significantly. This decline coincides with a reduction in the generation of new ureteric bud branches and a wave of new nephron formation ([@bib67]), and agrees with the kidney lymphatic vessel expansion we observed after E15.5. We also assessed the morphology of clusters within mouse embryonic kidneys using 3D segmentation and volume rendering ([Figure 2D](#fig2){ref-type="fig"}). At each timepoint, we arranged volume-rendered clusters from any single kidney into a hierarchy, starting with isolated PROX1^+^/LYVE-1^+^ cells through to large islands containing eight cells or more.

To investigate whether VEGF-C might also be involved in the formation of kidney lymphatic clusters, we isolated and cultured intact E14.5 metanephroi ex vivo ([Figure 2E](#fig2){ref-type="fig"}). 3D imaging demonstrated scattered PROX1^+^/LYVE-1^+^ clusters in control metanephroi after 48 hr in culture, and their abundance increased significantly upon supplementation of the culture media with recombinant VEGF-C (p*=*0.0184; [Figure 2---video 2](#fig2video2){ref-type="video"}). As multiple stages of cluster development exist within any single kidney and the decline in cluster frequency coincides with rapid lymphatic vessel expansion, we propose that both lymphangiogenesis and lymphvasculogenesis contribute to the formation of the mature kidney lymphatic vasculature and that both are regulated by VEGF-C.

Lymphatic development has been described predominantly in model organisms such as mouse and zebrafish ([@bib65]). Prior studies addressing normal human lymphatic development ([@bib75]; [@bib10]; [@bib28]; [@bib3]) have mostly examined systemic lymphatics and have only used single markers such as podoplanin. Thus, it is still not clear whether events observed in animal models can be extrapolated to lymphatic development in human organs. Moreover, human kidney development has been described and thoroughly compared with that of mouse ([@bib39]; [@bib40]), though the existence of lymphatic vessels during this process has not yet been examined. To image lymphatic vessels during human kidney development, we acquired millimeter-thick slices from human fetal kidneys at 12PCW. This stage marks the end of the first trimester in human gestation, designated the fetal stage of human organogenesis, and the human kidney at this stage is approximately equivalent to the E15.5 mouse kidney ([@bib41]). We used 3D reconstructions of 12PCW human kidneys to identify PROX1^+^/podoplanin^+^ lymphatic vessels, including large patent lymphatic vessels in the renal hilum and extensive networks of vessels in the maturing cortex ([Figure 3A](#fig3){ref-type="fig"}). Analogous to mouse, we identified a population of PROX1^+^/podoplanin^+^ lymphatic endothelial cell clusters in 12PCW human kidneys ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---video 1](#fig3video1){ref-type="video"}) that were structurally distinct from bona fide lymphatic vessels. Thus, the existence of lymphatic endothelial cell clusters in the kidney is likely a conserved feature in mammalian development. These clusters, akin to those previously described in the dermis, mesentery, meninges and heart, may represent a tissue-specific population of lymphatic progenitor cells, and our work provides the first demonstration of their existence in a developing human organ.

![Lymphatic vessels and clusters in the 12PCW human fetal kidney.\
(**A**) Representative 3D reconstructions of 1 mm-thick kidney slices from three independent human fetal kidneys at 12PCW, each stained for PROX1 and podoplanin. We observed PROX1^+^/podoplanin^+^ lymphatic vascular networks in the renal hilum and cortex (white arrowheads). Large caliber vessels were visible in the renal hilum (white asterisks). Scalebars: 200 μm. (**B**) Representative 3D reconstructions of junction between the renal hilum and cortex (dashed line) reveals a distinct lymphatic endothelial cell cluster (white boxed region) expressing PROX1 and podoplanin. This was structurally distinct from lymphatic vessels (white arrowheads) in this region of 12PCW kidneys and are shown in higher magnification in the optical *z-*sections (right three panels). Adjacent to the cluster (white arrowhead in optical z-section) were PROX1^+^/podoplanin^-^ cells of unknown identity (white asterisk). Scalebar: 200 μm (3D reconstruction); 20 μm (optical *z-*section). PROX1 expression was also found in tubular epithelial cells at 12PCW (yellow asterisks throughout). C, cortex; H, hilum; T, tubular epithelium.](elife-48183-fig3){#fig3}

Defective renal lymphatic vascular architecture in polycystic kidney disease {#s2-3}
----------------------------------------------------------------------------

We then sought to translate our 3D imaging and analysis strategy to a pathological setting in which kidney lymphatic development might be affected. We examined a mouse model of the most prevalent genetic renal anomaly, polycystic kidney disease (PKD), which features the accumulation of fluid-filled epithelial cysts within the kidney that drive renal inflammation and fibrosis ([@bib4]). We had several reasons for hypothesizing that kidney lymphatics are altered in PKD. Firstly, the gene responsible for the majority of cases of autosomal dominant (AD)PKD, *Pkd1,* is known to regulate extra-renal lymphatic endothelial cell migration and lymphatic vessel morphogenesis, as edema and structural defects in lymphatic vasculature have been observed in *Pkd1* mutant zebrafish and mice ([@bib13]; [@bib52]). Secondly, the endothelial knockout of *Pkd1* in mice decreased branching and increased diameter of dermal lymphatic vessels ([@bib39]). Finally, delivery of recombinant VEGF-C increased the abundance of lymphatics within the kidney and reduced disease severity in two mouse models of PKD ([@bib26]). However, despite a putative link to PKD, the phenotype of lymphatics in polycystic kidneys and their relationship to cysts have not yet been examined.

We assessed the lymphatic vasculature in kidneys from mouse embryos carrying a *Pkd1* p.R3277C allele (*Pkd1^RC^)*. This incompletely penetrant allele in homozygosity causes adult onset ADPKD ([@bib24]; [@bib61]). In homozygous mice (*Pkd1^RC/RC^*), the slow growth of kidney cysts is considered to mimic the temporal progression of human ADPKD compared with other more rapidly progressive mouse models ([@bib22]). Similar to knockouts of *Pkd1* ([@bib13]) or mice lacking key genes involved in lymphatic development ([@bib78]; [@bib30]; [@bib5]; [@bib18]), we found that *Pkd1^RC/RC^* homozygous embryos presented with subcutaneous edema at E15.5 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Using conventional histology ([Figure 4A](#fig4){ref-type="fig"}) we discerned corticomedullary cysts lined by tubular epithelial cells in E18.5 *Pkd1^RC/RC^* kidneys but not in wildtype littermate controls (*Pkd1^+/+^*), consistent with early stages of cyst formation. These cysts were in close proximity to cortical lymphatic vessels ([Figure 4---video 1](#fig4video1){ref-type="video"}). The proximity between lymphatics and cysts suggests that excess tissue fluid in PKD may be able to enter lymphatic vessels *via* paracellular transport ([@bib72]) and that there might be direct or indirect molecular interactions between cyst epithelium and lymphatic endothelial cells ([@bib26]).

![Identification of kidney lymphatic vessel defects in the *Pkd1^RC^* mouse model.\
(**A**) Representative brightfield images of four histology slides each from right kidneys of three independent *Pkd1^RC/RC^* or *Pkd1^+/+^* mouse embryos at E18.5. We cut 5 μm sections cut from the middle of *Pkd1^RC/RC^* and *Pkd1^+/+^* kidneys and stained with periodic acid-Schiff. Panels on the right show magnified images of the boundary between the cortex and medulla in either group (boxed region in low magnification images), where corticomedullary cysts (white arrowheads) are visible in *Pkd1^RC/RC^* kidneys at this timepoint. Glomeruli in either group are shown with black asterisks. Scalebars: 200 μm. C, cortex; M, medulla. (**B**) Volume rendered kidneys and lymphatic vessels in *Pkd1^RC/RC^* and *Pkd1^+/+^* kidneys. Overall, the lymphatic network appeared stunted in homozygous mutants and regions within the peripheries of their kidneys were unoccupied by lymphatic vessels at this stage (see black asterisks). Scalebars: 500 μm. (**C**) Filament tracing and color-coded visualization reveals a structural defect in large-caliber lymphatic vessel diameter in *Pkd1^RC/RC^* mice at E18.5. Each vessel branch is color-coded on a spectrum, from the smallest diameter vessels (average branch diameter \<20 μm) colored in purple to the largest vessel branch (average branch diameter \>70 μm) colored in red. Insets on the left showed the magnified region of the plexus on the right, corresponding to the ring-like anastomosis at the base of the plexus. The large diameter red colored vessel branches in the *Pkd1^+/+^* kidneys (white arrowhead) are absent in the equivalent region in *Pkd1^RC/RC^* kidneys (black asterisk). Scalebars: 50 μm. (**D**) Comparison of maximum vessel diameter in *Pkd1^+/+^* and *Pkd1^RC/RC^* kidneys at E18.5. An unpaired Student's *t-*test showed that the maximum lymphatic vessel diameter was significantly reduced in *Pkd1^RC/RC^* kidneys (*t = 3.6* p=0.0087). (**E**) Lymphatic vessel branches and total lymphatic network volume are reduced per unit of kidney volume in *Pkd1^RC/RC^* kidneys. ANOVA showed that both the number of vessel branches per mm of kidney (*t* = 2.6, p=0.0418) and the percentage occupancy of the volume of the kidney by lymphatic vessels (Welch's corrected *t* = 3.4, p=0.0367) were significantly reduced in homozygous mutants compared to wildtype controls at this timepoint. Welch's correct was applied when testing percentage occupancy of the total kidney volume by lymphatic vessels, as the two groups did not have equality of variances for this parameter. All kidneys from this analysis were pooled from a total of three independent litters. In all graphs, each data point represents the right kidney from an individual embryo and error bars represent standard error of the mean. Raw data and results of all statistical tests are presented in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
Figure 4---source data 1.This spreadsheet contains the numerical raw data and statistics for the quantitative analysis of kidney lymphatic vessel phenotypes in the *Pkd1^RC^* mouse model at E18.5 shown in [Figure 4D](#fig4){ref-type="fig"}, [Figure 4E](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.](elife-48183-fig4){#fig4}

To visualize the renal lymphatics in the *Pkd1^RC^* model, we generated 3D visual models of PROX1^+^/LYVE-1^+^ segmented lymphatic networks and observed a stunted appearance of lymphatics in *Pkd1^RC/RC^* compared with *Pkd1^+/+^* kidneys at E18.5 ([Figure 4B](#fig4){ref-type="fig"}). Interestingly, we found that the lymphatic network of E18.5 *Pkd1^+/+^* kidneys, raised on a C57Bl/6 background, was more extensive than that of CD-1 mice assessed at the same embryonic day (see [Figure 1B](#fig1){ref-type="fig"}). Differences between mouse strains have also been observed when analyzing the incidence of subcutaneous edema, hemorrhage and embryonic lethality upon knockout of key transcription factors or micro-RNAs governing lymphatic development ([@bib18]; [@bib36]).

To screen for more subtle lymphatic abnormalities in the kidneys of *Pkd1^RC/RC^* mice, we used filament tracing software to generate color-coded models of vessel diameter at E18.5 ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---video 2](#fig4video2){ref-type="video"}). We found large caliber vessels (diameter \>70 μm), present at the base of the lymphatic plexus in *Pkd1^+/+^* kidneys, constituting the ring-like anastomosis in the renal hilum. There were no lymphatic vessels of this large diameter in the equivalent region within *Pkd1^RC/RC^* kidneys at E18.5. Quantitative analysis confirmed this phenotype ([Figure 4D](#fig4){ref-type="fig"}), finding a significant reduction by 18% in the mean diameter of the largest lymphatic vessel in *Pkd1^RC/RC^* kidneys compared to *Pkd1^+/+^* controls (p*=*0.0087). In contrast, no significant differences were observed in the total number of vessel branches, the range of vessel branch lengths, the total volume of the lymphatic network between homozygous mutants and wildtype controls ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Although the kidney volume was not significantly different between the two groups, we derived that the number of lymphatic vessel branches per unit kidney volume (p*=*0.0418) and the proportion of kidney volume occupied by lymphatics (p*=*0.0367) were significantly reduced in *Pkd1^RC/RC^* kidneys compared to *Pkd1^+/+^* controls ([Figure 4E](#fig4){ref-type="fig"}). The complex global defect in kidney lymphatic vessel development in the *Pkd1^RC^* model, together with the close cyst-lymphatic relationship, suggests that inadequate clearance of tissue fluid by lymphatic vessels may contribute to the expansion of cysts in PKD.

Conclusion {#s2-4}
----------

In summary, we have combined advanced 3D imaging with structural rendering to provide novel spatial, temporal and quantitative insights into the formation of lymphatic vessels in developing mouse and human kidneys. By creating 3D images of kidney lymphatic vessels at single-cell resolution, we were able to visually and quantitatively demonstrate a period of quiescence, followed by extensive remodeling and expansion of the lymphatic plexus during renal development in mouse, in a process that is likely promoted by VEGF-C. The timing of plexus expansion in mouse kidneys coincides with the appearance of a highly dynamic population of lymphatic endothelial cell clusters, structurally distinct from bona fide lymphatic vessels. These clusters responded to VEGF-C and were conserved in human fetal kidneys. Our imaging approach further revealed defects in lymphatic architecture in polycystic kidneys. Together, we present a comprehensive study of the lymphatic vasculature in the developing mammalian kidney, provide the first evidence that lymphvasculogenesis is conserved in humans and implicate lymphatic anomalies in the pathophysiology of PKD.

Materials and methods {#s3}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type                         Designation                                   Source (publication)                                                                                                                                                                                 Identifier                                                           Additional information
  ------------------------------------ --------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Biological sample (*Mus musculus)*   CD-1 wildtype mouse                           Charles River                                                                                                                                                                                        Crl:CD1(ICR)                                                         Maintained as a random\
                                                                                                                                                                                                                                                                                                                                                               bred closed colony\
                                                                                                                                                                                                                                                                                                                                                               in house

  Biological sample\                   *Vegfc^LacZ^* mouse                           See [@bib30]                                                                                                                                                                                         Vegfc^tm1Ali^\                                                       *Vegfc^LacZ/+^* males mated with *Vegfc^+/+^* females to generate experimental\
  (*Mus musculus)*                                                                                                                                                                                                                                                                        RRID:[IMSR_EM:10734](https://scicrunch.org/resolver/IMSR_EM:10734)   litters, maintained on a CD-1 background

  Biological sample\                   *Pkd1* p.R3277C mouse                         See [@bib24]                                                                                                                                                                                         Pkd1^tm1.1Pcha^\                                                     *Pkd1^RC/+^* animals mated\
  (*Mus musculus)*                                                                                                                                                                                                                                                                        RRID: [MGI:5476836](https://scicrunch.org/resolver/MGI:5476836)      to generate experimental\
                                                                                                                                                                                                                                                                                                                                                               litters, maintained on a\
                                                                                                                                                                                                                                                                                                                                                               C57BL/6 background

  Biological sample (*Homo sapiens)*   Human fetal kidney                            Human Developmental\                                                                                                                                                                                 \-                                                                   Material obtained at 12PCW
                                                                                     Biology Resource ([@bib20])                                                                                                                                                                                                                                               

  Peptide, recombinant protein         Vascular endothelial\                         R and D Systems                                                                                                                                                                                      Cat\# 9199-VC-025                                                    Added to culture\
                                       growth factor C                                                                                                                                                                                                                                                                                                         medium at 40 ng/ml

  Sequence-based reagent               *Pkd1^RC^*\_F                                 See [@bib24]                                                                                                                                                                                         PCR primers                                                          CAAAGGTCTGGGTGATAACTGGTG

  Sequence-based\                      *Pkd1^RC^*\_R                                 See [@bib24]                                                                                                                                                                                         PCR primers                                                          CAGGACAGCCAAATAGACAGGG
  reagent                                                                                                                                                                                                                                                                                                                                                      

  Antibody                             Anti-PROX1\                                   R and D\                                                                                                                                                                                             Cat\# AF2727\                                                        Wholemount immunofluorescence (1:200) in mouse and human.\
                                       (Goat polyclonal)                             Systems                                                                                                                                                                                              RRID:[AB_2170716](https://scicrunch.org/resolver/AB_2170716)         Transcription factor labelling\
                                                                                                                                                                                                                                                                                                                                                               nuclei of lymphatic endothelium ([@bib78])\
                                                                                                                                                                                                                                                                                                                                                               and some\
                                                                                                                                                                                                                                                                                                                                                               tubular epithelium within the\
                                                                                                                                                                                                                                                                                                                                                               kidney ([@bib34])

  Antibody                             Anti-PROX1\                                   Millipore                                                                                                                                                                                            Cat\# ABN278\                                                        Wholemount immunofluorescence\
                                       (Rabbit polyclonal)                                                                                                                                                                                                                                RRID:[AB_2811075](https://scicrunch.org/resolver/AB_2811075)         (1:200) in mouse only.\
                                                                                                                                                                                                                                                                                                                                                               \
                                                                                                                                                                                                                                                                                                                                                               \

  Antibody                             Anti-LYVE-1\                                  Abcam                                                                                                                                                                                                Cat\# ab14917\                                                       Wholemount immunofluorescence (1:100) in mouse only. Labels\
                                       (rabbit polyclonal)                                                                                                                                                                                                                                RRID:[AB_301509](https://scicrunch.org/resolver/AB_301509)           lymphatic endothelial cell surface\
                                                                                                                                                                                                                                                                                                                                                               ([@bib2]). Present\
                                                                                                                                                                                                                                                                                                                                                               on F4/80^+^ macrophages\
                                                                                                                                                                                                                                                                                                                                                               and venous endothelium in\
                                                                                                                                                                                                                                                                                                                                                               the developing mouse kidney\
                                                                                                                                                                                                                                                                                                                                                               ([@bib38])

  Antibody                             Anti-LYVE-1\                                  R and D\                                                                                                                                                                                             Cat\# AF2125\                                                        Colorimetric immunohistochemistry\
                                       (goat polyclonal)                             Systems                                                                                                                                                                                              RRID:[AB_2297188](https://scicrunch.org/resolver/AB_2297188)         (1:20) of *Vegfc^LacZ/+^* mouse kidney\
                                                                                                                                                                                                                                                                                                                                                               sections.

  Antibody                             Anti-podoplanin (Syrian hamster monoclonal)   ThermoFisher\                                                                                                                                                                                        Cat\# 14-5381-82\                                                    Wholemount immunofluorescence\
                                                                                     Scientific                                                                                                                                                                                           Clone: 8.1.1\                                                        (1:100) in mouse only.\
                                                                                                                                                                                                                                                                                          RRID:[AB_1210505](https://scicrunch.org/resolver/AB_1210505)         Expressed on lymphatic\
                                                                                                                                                                                                                                                                                                                                                               endothelial cell membranes\
                                                                                                                                                                                                                                                                                                                                                               ([@bib77]; [@bib7]).\
                                                                                                                                                                                                                                                                                                                                                               Also expressed on podocytes\
                                                                                                                                                                                                                                                                                                                                                               within the developing and mature kidney\
                                                                                                                                                                                                                                                                                                                                                               ([@bib6])

  Antibody                             Anti-podoplanin (Mouse monoclonal)            Agilent                                                                                                                                                                                              Cat\# M361929-2\                                                     Wholemount immunofluorescence (1:100) in human only.\
                                                                                                                                                                                                                                                                                          Clone: D2-40\                                                        Expressed on lymphatic\
                                                                                                                                                                                                                                                                                          RRID:[AB_2162081](https://scicrunch.org/resolver/AB_2162081)         endothelial cell membranes\
                                                                                                                                                                                                                                                                                                                                                               within the human fetal kidney ([@bib28]).

  Antibody                             Anti-VEGFR-3 (Goat polyclonal)                R and D\                                                                                                                                                                                             Cat\# AF743\                                                         Wholemount immunofluorescence\
                                                                                     Systems                                                                                                                                                                                              RRID:[AB_355563](https://scicrunch.org/resolver/AB_355563)           (1:100) in mouse only. Expressed\
                                                                                                                                                                                                                                                                                                                                                               on lymphatic endothelial cell\
                                                                                                                                                                                                                                                                                                                                                               membranes and blood\
                                                                                                                                                                                                                                                                                                                                                               endothelia in the developing\
                                                                                                                                                                                                                                                                                                                                                               kidney ([@bib32]; [@bib29]).

  Antibody                             Anti-endomucin\                               Santa-Cruz                                                                                                                                                                                           Cat\# sc-53941\                                                      Wholemount immunofluorescence\
                                       (Rat monoclonal)                                                                                                                                                                                                                                   Clone: V.5C7\                                                        (1:50) in mouse only.
                                                                                                                                                                                                                                                                                          RRID:[AB_2100038](https://scicrunch.org/resolver/AB_2100038)         

  Antibody                             Anti-PECAM-1\                                 BD Biosciences                                                                                                                                                                                       Cat\# 553370\                                                        Wholemount immunofluorescence\
                                       (Rat monoclonal)                                                                                                                                                                                                                                   Clone: MEC13.3\                                                      (1:50) in mouse only.
                                                                                                                                                                                                                                                                                          RRID:[AB_394816](https://scicrunch.org/resolver/AB_394816)           

  Antibody                             Anti-F4/80 (Rat monoclonal)                   Bio-Rad                                                                                                                                                                                              Cat\# MCA497\                                                        Wholemount immunofluorescence\
                                                                                                                                                                                                                                                                                          Clone: Cl:A3.1\                                                      (1:50) in mouse only.
                                                                                                                                                                                                                                                                                          RRID:[AB_2098196](https://scicrunch.org/resolver/AB_2098196)         

  Antibody                             Anti-UPK3A (Rabbit polyclonal)                Abcam                                                                                                                                                                                                Cat\# ab82173\                                                       Wholemount immunofluorescence\
                                                                                                                                                                                                                                                                                          RRID:[AB_2213493](https://scicrunch.org/resolver/AB_2213493)         (1:100) in mouse only.

  Antibody                             Anti-AQP2\                                    Abcam                                                                                                                                                                                                Cat\# ab15116\                                                       Wholemount immunofluorescence\
                                       (Rabbit polyclonal)                                                                                                                                                                                                                                RRID:[AB_301662](https://scicrunch.org/resolver/AB_301662)           (1:100) in mouse only.

  Other                                Hoechst 33342                                 Life\                                                                                                                                                                                                Cat\# H3570                                                          Nuclear counterstain.\
                                                                                     Technologies                                                                                                                                                                                                                                                              Wholemount immunofluorescence\
                                                                                                                                                                                                                                                                                                                                                               (1:2000)

  Software, algorithm                  ImageJ/FIJI                                   [https://imagej.net/Welcome](https://imagej.net/Welcome74) ([@bib64])                                                                                                                                RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)         Version 2.0

  Software, algorithm                  Zen                                           <https://www.zeiss.com/microscopy/int/products/microscope-software/zen.html>                                                                                                                         \-                                                                   \-

  Software, algorithm                  Imaris                                        <http://www.bitplane.com>                                                                                                                                                                            RRID:[SCR_007370](https://scicrunch.org/resolver/SCR_007370)         Version 8.2. Imaris FilamentTracer\
                                                                                                                                                                                                                                                                                                                                                               used in this paper (RRID:[SCR_007366](https://scicrunch.org/resolver/SCR_007366))

  Software, algorithm                  Amira                                         <https://www.thermofisher.com/uk/en/home/industrial/electron-microscopy/electron-microscopy-instruments-workflow-solutions/3d-visualization-analysis-software/amira-life-sciences-biomedical.html>   RRID:[SCR_007353](https://scicrunch.org/resolver/SCR_007353)         Version 5.4
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Acquisition of mouse embryonic and human fetal kidneys {#s3-1}
------------------------------------------------------

All experiments were carried out according to a UK Home Office project license (PPL: PE52D8C09) and were compliant with the UK Animals (Scientific Procedures) Act 1986. To assess lymphatic development in wildtype mouse kidneys, we collected embryos from outbred CD-1 mice; maintained as a random bred closed colony at our facility. To determine the expression of VEGF-C during kidney development, we mated *Vegfc^LacZ/+^* males ([@bib30]), backcrossed to a CD-1 background, with CD-1 wildtype females and collected embryos at desired timepoints. For analysis of lymphatic development in a mouse model of PKD, we performed matings between mice heterozygous for the *Pkd1^RC^* mutation ([@bib24]) on a C57BL/6 background to generate experimental litters. For all mouse experiments, matings were set up in the evening and copulation plugs found the following morning at 9am were designated E0.5. At the desired timepoint, pregnant dams were sacrificed by CO~2~ inhalation and death confirmed by cervical dislocation. Mouse embryos were excised from the uterus and dissected in 1 x phosphate-buffered saline (PBS). Tails were acquired and stored at −20°C from embryos obtained from pregnant *Pkd1^RC/+^* heterozygous females for genotyping, which was performed as previously described ([@bib24]). At this point, embryos generated from *Pkd1^RC/+^* crosses were imaged using a Zeiss Axio Lumar V12 stereomicroscope. Human fetal kidneys were obtained from the Human Developmental Biology Resource (<http://www.hdbr.org>), which obtains written consent from donors to collect, store and distribute human fetal material between 4-20PCW ([@bib20]). Following dissection, human fetal material was maintained in tissue culture medium at 4°C. With the exception of *Vegfc^LacZ/+^* kidneys, we immediately washed all biological material in washed in 1 x PBS to remove blood, fixed the tissues overnight in 4% (w/v) paraformaldehyde (PFA) in PBS at 4°C, and washed tissues twice in PBS the next day. Human fetal kidneys were then incubated in 30% (w/v) sucrose in PBS overnight at 4°C, prior to embedding in 4% (w/v) agarose in PBS and slicing at 1 mm on a vibrating blade microtome (VT1000S, Leica Biosystems). We subsequently stored all material in PBS with 0.02% (w/v) sodium azide at 4°C.

Wholemount X-gal staining and imaging {#s3-2}
-------------------------------------

*Vegfc^LacZ/+^* or *Vegfc^+/+^* kidneys were fixed in 2% PFA for 20 min on ice. They were then washed thrice for five mins each in PBS, before incubating at 37°C in stain solution (5 mM potassium ferricyanide, 5 mM potassium hexacyanoferrate (III) trihydrate, 2 mM magnesium chloride and 0.01% (w/v) sodium deoxycholate in PBS) with X-gal in a 1:40 ratio. The X-gal reaction was quenched by washing twice in PBS with 0.02% sodium azide. Wholemount X-gal images were captured using a Leica MZFLIII stereomicroscope with an IDS UI-3080CP-C-HQ camera and micromanager software.

Histology, colorimetric immunohistochemistry and brightfield imaging {#s3-3}
--------------------------------------------------------------------

*Pkd1^RC/RC^*, *Pkd1^+/+^* or X-gal-stained *Vegfc^LacZ/+^* kidneys were dehydrated in an ethanol series prior to incubation in Histo-Clear II (National Diagnostics) and embedding in paraffin wax. Sections were cut at 5 μm using a microtome. Deparaffinization and staining with periodic acid-Schiff was performed as previously described ([@bib8]). Colorimetric immunostaining of *Vegfc^LacZ/+^* kidney sections for LYVE-1 was performed using a goat anti-mouse LYVE-1 with horseradish peroxidase rabbit anti-goat secondary antibody. Brightfield imaging was performed using an upright Zeiss Axioplan microscope equipped with a Zeiss Axiocam HRc camera and Axiovision software.

Ex vivo culture of mouse embryonic kidneys {#s3-4}
------------------------------------------

Freshly isolated kidneys were obtained from E14.5 CD-1 mice, explanted on Millicell cell culture inserts (Millipore) and incubated at 37°C in 20% O~2~ and 5% CO~2~. Explants were grown at the air-liquid interface with Dulbecco\'s Modified Eagle Medium/Nutrient Mixture F-12 (Gibco), supplemented with or without 40 ng/ml recombinant VEGF-C. The culture medium was replaced 24 hr after initiation of the experiment. After 48 hr in culture, explants were collected in PBS, fixed in 4% PFA overnight and processed for wholemount immunolabelling, optical clearing and confocal microscopy (see below). Infected explants and those that had not adhered to the cell culture membrane were discarded. Data were pooled from two independent experiments, each from a separate litter of CD-1 embryos.

Wholemount immunofluorescence and optical clearing {#s3-5}
--------------------------------------------------

For mouse embryonic kidneys, a modified version of the iDISCO pipeline ([@bib60]) was performed for wholemount indirect immunolabelling using antibodies and concentrations indicated in the **Key resources table,** with all steps performed on rotating shakers ([@bib27]). We first dehydrated mouse embryonic kidneys in a methanol series at room temperature (RT) and bleached in methanol with 5% (v/v) of 30% hydrogen peroxide (H~2~O~2~) solution overnight at 4°C. They were then rehydrated at RT and permeabilized in PBS with 0.2% (v/v) Triton X-100, 2.3% (w/v) glycine and 20% (v/v) dimethyl sulfoxide (DMSO) overnight at 4°C. Blocking was then performed in PBS with 0.2% Triton X-100, 6% (v/v) donkey serum and 10% DMSO at RT for one day, and incubated in 500 μl of wash buffer (PBS solution with 0.2% (v/v) Tween-20, 0.1% (v/v) of 10 mg/ml heparin stock solution) with 3% donkey serum, 5% DMSO and primary antibody for three days at 4°C. The labelled kidneys were then incubated in washing buffer 4--6 times for 1 hr each at RT. Secondary antibodies, either AlexaFluor 488, 546 or 633 (ThermoFisher Scientific) were then added at a concentration of 1:200 in 500 μl of wash buffer with 3% donkey serum and 5% DMSO and incubated at 4°C overnight, before 4--6 applications of washing buffer alone for 1 hr each. Hoechst was added with secondary antibodies for selected *Pkd1^RC/RC^* or *Pkd1^+/+^* kidneys.

The wholemount immunofluorescence process was similar for millimeter-thick vibratome slices of 12PCW human kidneys, but instead adapting a protocol optimized for human embryonic and fetal material ([@bib3]). The protocol was identical to above, but involved the following changes: (1) bleaching was performed in 10% of 30% H~2~O~2~ solution; (2) permeabilization was performed at RT in 1 x PBS with 0.2% (w/v) bovine gelatin with 0.2% Triton X-100 (PBSGT) with 20% DMSO overnight; (3) all wash steps were performed in PBSGT; (4) Blocking was performed in PBSGT with 10% DMSO and 3% donkey serum and (5) Primary and secondary antibody incubations were performed in 1 ml of PBSGT with 0.1% (w/v) saponin, 5% DMSO and 3% donkey serum at 37°C for six days, and primary antibodies were replenished after three days. After immunolabelling, both mouse embryonic kidneys and human kidney slices were dehydrated in a methanol series at RT, adapted for clearing using a 1:1 mixture of methanol and 1:2 benzyl alcohol:benzyl benzoate, termed BABB ([@bib11]; [@bib16]), and finally cleared in BABB alone until optically transparent.

Confocal imaging with single- or two-photon excitation {#s3-6}
------------------------------------------------------

All confocal images were acquired using a Zeiss LSM 880 Upright Confocal Multiphoton microscope with gallium arsenide phosphide internal and external detectors and a 10x/numerical aperture 0.5 water dipping objective (working distance: 3.7 mm) with 2.77 μm z-step. To protect the microscope objective from BABB, we suspended smaller tissues (E14.5--16.5 mouse kidneys) in a drop of BABB within a glass-bottomed FluoroDish (World Precision Instruments), which was inverted for upright confocal imaging. Larger tissues (E17.5--18.5 mouse kidneys and 12PCW human kidney slices) were placed in BABB within a custom imaging chamber, consisting of an FKM rubber ring (Polymax) between a glass slide and coverslip. Prior to imaging, a drop of distilled water was placed on top of the inverted FluoroDish or coverslip, into which the objective was placed. For single-photon excitation we used laser lines at 488, 561 and 633 nm. For two-photon excitation, a Mai Tai eHP DeepSee multiphoton laser (SpectraPhysics, 800 nm) was used. Confocal *z-*stacks were acquired as 8-bit images with pixel resolutions of 512 × 512 or 1024 × 1024. For E16.5--18.5 mouse embryonic kidneys and 12PCW human fetal kidney slices, tile scanning was performed with a 10% overlap between each image tile. All images were saved as CZI files.

Image processing and analysis {#s3-7}
-----------------------------

We use the Stitching tool in Zen software (Zeiss) to stitch together tile scans acquired from confocal imaging. In kidneys from the *Pkd1^RC^* mouse model stained with Hoechst or in highly autofluorescence 12PCW human kidney slices, spectral unmixing was performed in Zen to separate nuclear counterstaining and autofluorescence respectively from spill-over into other fluorescence channels. Images were then exported to FIJI. Confocal image stacks were separated into individual fluorescence channels and Despeckle and Sharpen tools were used to reduce non-specific background fluorescence. Where maximum intensity projections or optical *z-*sections were required, scalebars applied and exported as TIFF files. TIFF files were further imported into Imaris (Bitplane) where 3D reconstruction, segmentation or analysis, volume rendering or videos were required.

Segmentation and volume rendering {#s3-8}
---------------------------------

To segment lymphatic vessel and clusters from mouse embryonic kidneys, we used the Isosurface Rendering tool in Imaris. Segmentation of the LYVE-1 channel was performed based on fluorescence intensity, and thresholds were manually selected to capture PROX1^+^/LYVE-1^+^ structures. To isolate the lymphatic vessel plexus alone, a filter was applied to retain structures with the largest volume. Thereafter, we generated masks selecting for expression of both PROX1 and LYVE-1 only, generating new channels with either unedited fluorescence intensity (as in [Figure 2A](#fig2){ref-type="fig"} and [Figure 4---video 1](#fig4video1){ref-type="video"}) or binarized for filament tracing analysis. We volume-rendered and segmented lymphatic vessels and clusters in Imaris to generate the 3D models shown in [Figure 1B](#fig1){ref-type="fig"} and [Figure 4B](#fig4){ref-type="fig"}. Due to the high sensitivity of the two-photon detection system, we generated a custom script in FIJI to create a new fluorescence channel containing segmented and binarized PROX1^+^/LYVE-1^+^ lymphatic vessels from *Pkd1^RC/RC^* or *Pkd1^+/+^* kidneys. Briefly, PROX1^+^ nuclei and LYVE-1^+^ cells were separately segmented to form masks using a rolling ball background subtraction, auto-thresholding and the 3D Simple Segmentation plugin. The nuclear and cellular masks were overlaid to create a new image channel containing only PROX1^+^/LYVE-1^+^ cells. These were then exported into IMARIS as TIFF files alongside the original channels and rendered using Imaris as above.

Filament tracing and quantification kidney lymphatic vascular development {#s3-9}
-------------------------------------------------------------------------

Color-coded 3D visualization of vascular parameters (as in [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"} or [Figure 4C](#fig4){ref-type="fig"}), such as vessel volume or diameter were generated using the FilamentTracer tool in Imaris from segmented PROX1^+^/LYVE-1^+^ lymphatic vessels. For quantitative analysis, TIFF image stacks were imported into Amira (ThermoFisher Scientific). The Filament Editor tool was used in Amira to generate spatial statistical parameters including vessel branch number, lengths, diameters and volumes from each segmented lymphatic plexus. These were exported as CSV files for graphing and statistical tests.

Quantification of lymphatic endothelial cell cluster frequency and total number of cluster cells {#s3-10}
------------------------------------------------------------------------------------------------

We defined clusters as PROX1^+^/LYVE-1^+^ cells with no continuity of PROX1^+^ nuclei with the lymphatic vessel plexus. To maximize specificity, clusters were quantified manually by rigorously scrolling through serial confocal images of entire mouse embryonic kidneys in FIJI. Where a cluster was observed, it was marked with the Multi-point tool to avoid counting the same clusters twice, and the number of cells within clusters was defined by the number of PROX1^+^ nuclei they contained. Where tile-scanning was performed, individual tiles were each inspected for the presence of clusters.

Estimation of total kidney volume, branches per unit kidney volume and proportion of the kidney occupied by lymphatic vessels {#s3-11}
-----------------------------------------------------------------------------------------------------------------------------

Total kidney volume was determined in a semi-automated fashion using FIJI. Series confocal images from each kidney had a Gaussian filter applied (σ = 5). Thresholding was applied using the Li method. A binary mask was then created, and holes filled before 3D Connected Component Analysis. The branches per unit volume of the kidney and total kidney volume occupied by lymphatic vessels were calculated by dividing the total number of vessel branches and the total lymphatic network volume of each kidney, derived from Filament Editor tool in Amira, by the total kidney volume as calculated above. Lymphatic vessel branches per unit kidney volume were expressed per mm, whereas the proportion of the kidney occupied by lymphatic vessels was expressed as a percentage of total kidney volume.

Sample size estimation {#s3-12}
----------------------

We estimated sample sizes based on preliminary experiments and prior quantitative analyses of developing cardiac ([@bib35]), dermal ([@bib55]) and mesenteric ([@bib69]) lymphatic vessels. For quantitative analysis of lymphatic development in wildtype mice, we predicted between 4--6 embryonic kidneys per timepoint would be sufficient to power experiments. For all experiments on wildtype mouse embryonic kidneys, 4--6 experimental repeats were randomly selected from kidneys pooled by litter at the required timepoint. In all cases, conclusions were drawn from a minimum of two to three independent litters per timepoint. For analysis of lymphatic abnormalities in the *Pkd1^RC^* model at E18.5, we analyzed the right kidney only and the left was taken for histology. All other sample sizes are shown in the relevant figure legends.

Statistical analysis and data presentation {#s3-13}
------------------------------------------

Storage, statistics and graphing of numerical data was performed in Prism (v8, GraphPad). A two-tailed p value of less than 0.05 was considered statistically significant for all tests. Shapiro-Wilk and Brown-Forsythe tests were used to test Gaussian distribution and equality of variance respectively within all datasets. Where Gaussian distribution and equality of variances were satisfied, we used ANOVA to compare vascular parameters or cluster number and cell content across all timepoints during renal development. Bonferroni tests for multiple comparisons were used to compare individual timepoints after ANOVA. Similarly, we used unpaired Student's *t*-test to compare vascular parameters in *Pkd1^RC/RC^* and *Pkd1^+/+^* kidney lymphatic vessels and to compare the effect of VEGF-C upon number of lymphatic clusters in mouse embryonic kidney explants. Where Gaussian distribution or equality of variances were violated, non-parametric tests and subsequent multiple comparisons were performed as detailed in the figure legends. All images were compiled into Microsoft PowerPoint where figures were created. All videos, 3D reconstructions, color-coded models and volume renderings were prepared in IMARIS and exported as MP4 or TIFF files. MP4 files were annotated in iMovie (v10.1, Apple Inc).

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/501100001282Great Ormond Street Institute of Child Health Child Health Research PhD Studentship to Daniyal J Jafree, Peter J Scambler, David A Long.

-   http://dx.doi.org/10.13039/501100000765University College London MB/PhD Studentship to Daniyal J Jafree.

-   http://dx.doi.org/10.13039/501100000265Medical Research Council MR/P018629/1 to David A Long.

-   http://dx.doi.org/10.13039/501100000265Medical Research Council MR/L002744/1 to Adrian S Woolf.

-   http://dx.doi.org/10.13039/501100000265Medical Research Council MR/K026739/1 to Adrian S Woolf.

-   http://dx.doi.org/10.13039/501100000274British Heart Foundation FS/19/14/34170 to Rosa Maria Correra.

-   http://dx.doi.org/10.13039/501100000361Diabetes UK 15/0005283 to David A Long.

-   http://dx.doi.org/10.13039/501100000272National Institute for Health Research NIHR Great Ormond Street Hospital Biomedical Research Centre Award 17DD08 to Dale Moulding.

-   http://dx.doi.org/10.13039/501100000274British Heart Foundation CH/11/1/28798 to Paul R Riley.

-   http://dx.doi.org/10.13039/501100000274British Heart Foundation RG/15/14/31880 to Peter Scambler.

-   http://dx.doi.org/10.13039/501100000291Kidney Research UK Paed_RP_10_2018 to Daniyal J Jafree, Adrian S Woolf, David A Long.

-   http://dx.doi.org/10.13039/501100000291Kidney Research UK IN_012_2019 to Daniyal J Jafree, David A Long.

We thank Professor Juan Pedro Martinez-Barbera (University College London), Dr Peter Baluk (University of California San Francisco) and Dr Nicolas Renier (L\'Institut du Cerveau et de la Moelle Épinière) for help and advice. All mice were maintained by staff at GOSICH Western Laboratories and UCL Biological Services. Microscopy was performed at the Light Microscopy Core Facility at UCL GOSICH. All work was performed with the support of the National Institute for Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.

Additional information {#s4}
======================

No competing interests declared.

Conceptualization, Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Project administration.

Resources, Data curation, Software, Visualization, Methodology.

Investigation, Methodology, Approved final version of the manuscript.

Investigation, Methodology, Approved final version of the manuscript.

Resources, Investigation, Project administration, Approved final version of the manuscript.

Investigation, Methodology, Approved final version of the manuscript.

Resources, Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Approved final version of the manuscript.

Investigation, Methodology, Approved final version of the manuscript.

Conceptualization, Resources, Approved final version of the manuscript.

Resources.

Conceptualization, Investigation, Writing - review and editing.

Resources, Software, Methodology.

Conceptualization, Validation, Methodology.

Conceptualization, Validation, Methodology.

Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Methodology, Project administration.

Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Methodology, Project administration.

Human subjects: Human fetal kidneys were obtained from the Human Developmental Biology Resource (http://www.hdbr.org), which obtains written consent from donors to collect, store and distribute human fetal material between 4-20PCW.

Animal experimentation: All experiments were carried out according to a UK Home Office project license (PPL: PE52D8C09) and were compliant with the UK Animals (Scientific Procedures) Act 1986.

Additional files {#s5}
================
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The FIJI script used for segmenting and binarizing PROX1+/LYVE1+ cells has been provided as Source code file 1. All raw numerical data and results of statistical tests are attached as source data for the appropriate figures.
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**Decision letter after peer review:**

Thank you for submitting your article \"Spatiotemporal dynamics and heterogeneity of mammalian kidney lymphatics in development and disease\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Dontscho Kerjaschki (Reviewer \#2).

Summary:

This study is novel and adds substantially to the field since very little is known about lymphangiogenesis (and lymphvasculogenesis) in kidney development and in disease. It uses state of the art imaging in embryonic kidney samples (including human). It convincingly describes initial steps in the genesis of renal lymphatic vessels in mice and man. The techniques used reveal stunning pictures and clearly illustrate the author\'s claims. The descriptions of lymphatic cell \"clusters\" is novel to kidney development.

The title of the paper is somewhat misleading and suggests that the study includes several diseases. Thus, a more specific title is needed.

One main concern is that the paper remains essentially descriptive. The first part of the manuscript describes lymphatic development in kidneys in detail. However, the relation to disease is the weakest part that is difficult to connect with the rest of the study. It is not clear how the phenotype of polycystic kidney is essentially related to the lymphatics.

Essential revisions:

*Pkd1* deletion can be induced in vasculature (Coxam et al., 2014). Any evidence of kidney defects in this model?

Could the authors provide co-localization of lymphatic markers with VEGF-C? It would add considerably to the manuscript if kidney VEGF-C expression was also shown in development in relation to lymphatic development. This would be of particular interest in the *Pkd1^RC/RC^*vs *Pkd1^+/+^* mice and should increase our understanding of why lymphatic vessel development is stunted in polycystic kidney disease. This might be possible on existing tissue collected from mice? Is VEGF-C required for the development of kidney lymphatics?

The authors should add a summary of the use of the different lymphatic markers and what they each may or may not relate to.

The lymphatic vessel diameter, branch points and volume between *Pkd1^+/+^* and CD1 mice at the same time in development (E18.5) seem very different. Even more so than between *Pkd1^RC/RC^*and *Pkd1^+/+^* mice. The authors should explain what is the explanation for these differences. Some discussion about differences in lymphatic development between mouse strains should be added.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Spatiotemporal dynamics and heterogeneity of renal lymphatics in mammalian development and cystic kidney disease\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Marianne Bronner (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance.

In the rebuttal, the authors note: \"However, our attempts at localising VEGF-C in kidney development using immunostaining or the*Vegfc^LacZ^* reporter mouse were thus far unsuccessful due to poor quality staining and a failure to obtain time-mated embryos at the required stages, respectively.\" This analysis should be completed, as it is necessary to support the claim that VEGF-C is responsible for lymphatic vessel growth in the kidney, when it could be VEGF-D instead. VEGF-C needs to be expressed (nearby) to make the claim in the manuscript.

10.7554/eLife.48183.sa2

Author response

> \[...\]
>
> The title of the paper is somewhat misleading and suggests that the study includes several diseases. Thus, a more specific title is needed.

As suggested, we have changed the title to "Spatiotemporal dynamics and heterogeneity of renal lymphatics during mammalian development and cystic kidney disease" to more accurately reflect the content of the paper.

> One main concern is that the paper remains essentially descriptive.

We agree that the original version of the manuscript was largely descriptive. However, given the lack of knowledge regarding lymphangiogenesis in kidney development and disease, we feel that high-quality descriptive studies such as ours are required to provide a basis for functional experiments in the future. As a starting point for functional work on the kidney lymphatics, we have performed an additional set of experiments in the revised paper by examining the potential role of VEGF-C in kidney lymphatic development. To do this, E14.5 kidneys were isolated and cultured ex vivo with or without recombinant VEGF-C. Three-dimensional imaging 48 hours later demonstrated scattered PROX1^+^/LYVE-1^+^ cell clusters in control kidney explants, whose abundance increased significantly in explants supplemented with recombinant VEGF-C. These new functional studies are presented in a revised Figure 2E and Figure 2---video 2 and provide evidence that VEGF-C promotes renal lymphatic development. Please see paragraph three of subsection "Characterization of conserved lymphatic endothelial cell clusters in the developing mammalian kidney" for the description of these new experiments in the main text.

> The first part of the manuscript describes lymphatic development in kidneys in detail. However, the relation to disease is the weakest part that is difficult to connect with the rest of the study. It is not clear how the phenotype of polycystic kidney is essentially related to the lymphatics.

We agree that our explanation for examining lymphatics in PKD could have been strengthened. We feel that there are several important strands of evidence to justify this link. Firstly, the gene responsible for the majority of cases of autosomal dominant (AD)PKD, *Pkd1,* is known to regulate lymphatic endothelial cell migration and lymphatic vessel morphogenesis, as edema and structural defects in lymphatic vasculature have been observed in *Pkd1* mutant zebrafish and mice (Outeda et al., 2014; Coxam et al., 2014). To translate these findings into putative link between lymphatics and PKD, we now show edema at E15.5 in *Pkd1^RC/RC^* mice, indicative of lymphatic defects in this model (new Figure 4---figure supplement 1). Secondly, the endothelial knockout of *Pkd1* in mice reduces branching and increases diameter of dermal lymphatic vessels (Coxam et al., 2014). Although the kidney was not examined in these studies, this evidence highlights a potential role for *Pkd1* in lymphangiogenesis. Thirdly, we showed in a prior study that delivery of recombinant VEGF-C both increases the abundance of renal lymphatics and reduces disease severity in two mouse models of PKD. The increase in the abundance of renal lymphatics may help to improve the edema and inflammation seen in these PKD models (Huang et al., 2016). Despite the putative link between lymphatics and PKD, the phenotype of lymphatics in polycystic kidneys and their relationship to cysts have not been examined. The results detailed in our manuscript are the first to identify structural anomalies of kidney lymphatics in a mouse model of PKD. The points raised above have been made in subsection "Defective renal lymphatic vascular architecture in polycystic kidney disease" of the revised manuscript to provide a stronger rationale for examining lymphatics in PKD.

> Essential revisions:
>
> Pkd1 deletion can be induced in vasculature (Coxam et al., 2014). Any evidence of kidney defects in this model?

*Pkd1* deletion has been performed in endothelium in mice using inducible *Sox18-Cre* and constitutive *Tie2-Cre* lines. The investigators showed that these mice had fewer lymphatic branch points and increased average width in the lymphatics of the skin (Coxam et al., 2014). We have highlighted this paper in more detail in the revised manuscript. Unfortunately, the kidneys were not examined in this study. To provide definitive evidence for a kidney lymphatic defect in mice lacking *Pkd1* in the vasculature would require use of multiple *Cre* lines in parallel and other experimental techniques to determine recombination efficiency and validate specific knockdown of *Pkd1* within lymphatics and/or endothelium. These experiments are ongoing in our laboratory. Instead, in our paper, we have selected to study the *Pkd1^RC^*mouse model, which mimics the temporal progression of human PKD and the kidney lymphatics of which not been studied until now.

> Could the authors provide co-localization of lymphatic markers with VEGF-C? It would add considerably to the manuscript if kidney VEGF-C expression was also shown in development in relation to lymphatic development. This would be of particular interest in the *Pkd1*^*RC/R*C^ vs *Pkd1^+/+^*mice and should increase our understanding of why lymphatic vessel development is stunted in polycystic kidney disease. This might be possible on existing tissue collected from mice? Is VEGF-C required for the development of kidney lymphatics?

We completely agree that an evaluation of VEGF-C in both kidney development and PKD would be informative. Indeed, our previous work demonstrated that mice homozygous for a hypomorphic *Pkd1* allele have reduced *Vegfc* mRNA in the early stages of cystogenesis (Huang et al., 2016). However, our attempts at localising VEGF-C in kidney development using immunostaining or the *Vegfc^LacZ^* reporter mouse were thus far unsuccessful due to poor quality staining and a failure to obtain time-mated embryos at the required stages, respectively.

We have therefore examined whether VEGF-C promotes kidney lymphatic development. To do this, we isolated and cultured CD-1 mouse embryonic kidneys at E14.5 with media with or without 40ng/ml of recombinant VEGF-C. After two days in culture, we used 3D imaging and found aggregates of PROX1^+^/LYVE-1^+^ cells, the abundance of which were significantly increased when VEGF-C was added to the culture medium (please refer to Figure 2E and Figure 2---video 2 and accompanying figure legends and paragraph three of subsection "Characterization of conserved lymphatic endothelial cell clusters in the developing mammalian kidney" in the revised article). Therefore, although the cellular sources of VEGF-C during kidney development remain an open question, this ex vivo experiment provides strong evidence that VEGF-C is involved in renal lymphatic development and adds a functional element to the paper.

> The authors should add a summary of the use of the different lymphatic markers and what they each may or may not relate to.

We have expanded the key resources table in the revised manuscript providing a summary of the lymphatic markers used, including the structures they label in lymphatic endothelial cells as well as information on other cell types which have been reported to express these markers in the developing kidney.

> The lymphatic vessel diameter, branch points and volume between *Pkd1^+/+^*and CD-1 mice at the same time in development (E18.5) seem very different. Even more so than between *Pkd1^RC/RC^*and *Pkd1^+/+^* mice. The authors should explain what is the explanation for these differences. Some discussion about differences in lymphatic development between mouse strains should be added.

We thank the reviewers for raising this important point. We agree that these differences reflect differences in the temporal progression of lymphatic development in different mouse strains. We have added text in subsection "Defective renal lymphatic vascular architecture in polycystic kidney disease" to highlight this point. In prior reports knocking out key transcription factors or micro-RNAs governing lymphatic development, there are strain-dependent differences in phenotypes, such as subcutaneous edema, hemorrhage and embryonic lethality (François et al., 2008; Kontarakis et al., 2018). As all quantitative analyses described in our paper only compare between mice on the same genetic background, the strain differences do not impact on the interpretation of our comparisons.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance.
>
> In the rebuttal, the authors note: \"However, our attempts at localising VEGF-C in kidney development using immunostaining or the *Vegfc^LacZ^* reporter mouse were thus far unsuccessful due to poor quality staining and a failure to obtain time-mated embryos at the required stages, respectively.\" This analysis should be completed, as it is necessary to support the claim that VEGF-C is responsible for lymphatic vessel growth in the kidney, when it could be VEGF-D instead. VEGF-C needs to be expressed (nearby) to make the claim in the manuscript.

We appreciate the favourable evaluation of the Editors and the reviewers to our previous revision and the opportunity to address the remaining issues. In this amended version of the paper, we have performed the requested analysis of VEGF-C in kidney development to support the claim that VEGF-C is responsible for lymphatic vessel growth in the kidney.

To do this, we have examined the developing kidneys of *Vegfc^LacZ^* mice (Karkkainen et al., 2004). Wholemount X-gal staining of E15.5 kidneys from heterozygous embryos (*Vegfc^LacZ/+^*) demonstrated β-galactosidase (β-gal) activity in a branching pattern, mimicking the appearance of the renal arterial tree. Sections of X-gal-stained E16.5 *Vegfc^LacZ/+^* kidneys showed β-gal activity to be restricted to interstitial cells beneath the pelvis and adjacent arterioles. We further stained these sections for LYVE-1 and observed lumenized LYVE-1^+^ vessels in the hilum surrounded by β-gal-expressing interstitial cells. Together, these findings convey that the renal hilum; where kidney lymphatics first arise, is a VEGF-C-rich niche which likely promotes renal lymphangiogenesis.

Our new data is presented in Figure 1---figure supplement 4 and outlined in the main text.
